Edgewise Therapeutics, Inc. (EWTX)
Largest Insider Buys in Sector
EWTX Stock Price History Chart
EWTX Stock Performance
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise …
Insider Activity of Edgewise Therapeutics, Inc.
Over the last 12 months, insiders at Edgewise Therapeutics, Inc. have bought $10.1M and sold $13.3M worth of Edgewise Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Edgewise Therapeutics, Inc. have bought $30.86M and sold $6.07M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ORBIMED ADVISORS LLC () — $175M. Thompson Peter A. () — $25M. Fox Jonathan C (director) — $100,958.
The last purchase of 454,545 shares for transaction amount of $5M was made by Thompson Peter A. () on 2024‑01‑23.
List of Insider Buy and Sell Transactions, Edgewise Therapeutics, Inc.
| 2024-09-23 | Sale | General Counsel | 20,922 0.0233% | $27.63 | $578,064 | +20.31% | ||
| 2024-09-20 | Sale | Chief Business Officer | 42,068 0.046% | $29.03 | $1.22M | +12.52% | ||
| 2024-09-20 | Sale | CMO | 7,162 0.0076% | $28.29 | $202,603 | +12.52% | ||
| 2024-09-20 | Sale | Chief Scientific Officer | 75,000 0.0799% | $28.27 | $2.12M | +12.52% | ||
| 2024-09-20 | Sale | Chief Financial Officer | 125,092 0.1348% | $28.57 | $3.57M | +12.52% | ||
| 2024-09-20 | Sale | General Counsel | 50,000 0.0535% | $28.37 | $1.42M | +12.52% | ||
| 2024-05-02 | Sale | Chief Financial Officer | 2,157 0.0023% | $18.91 | $40,789 | -4.66% | ||
| 2024-05-02 | Sale | CMO | 3,682 0.0039% | $18.91 | $69,627 | -4.66% | ||
| 2024-05-02 | Sale | President and CEO | 3,152 0.0033% | $18.91 | $59,604 | -4.66% | ||
| 2024-05-02 | Sale | Chief Business Officer | 1,718 0.0018% | $18.91 | $32,487 | -4.66% | ||
| 2024-05-02 | Sale | Chief Scientific Officer | 1,576 0.0017% | $18.91 | $29,802 | -4.66% | ||
| 2024-05-02 | Sale | General Counsel | 1,956 0.0021% | $18.91 | $36,988 | -4.66% | ||
| 2024-02-09 | Sale | Chief Business Officer | 4,800 0.0065% | $20.04 | $96,209 | -9.42% | ||
| 2024-02-09 | Sale | General Counsel | 8,029 0.0109% | $20.01 | $160,657 | -9.42% | ||
| 2024-02-08 | Sale | Chief Business Officer | 4,600 0.0063% | $20.01 | $92,049 | -10.85% | ||
| 2024-02-08 | Sale | General Counsel | 3,813 0.0052% | $20.01 | $76,285 | -10.85% | ||
| 2024-02-07 | Sale | Chief Business Officer | 600 0.0008% | $20.00 | $12,000 | -11.54% | ||
| 2024-02-07 | Sale | General Counsel | 17,993 0.0245% | $20.00 | $359,864 | -11.54% | ||
| 2024-01-23 | Sale | Chief Financial Officer | 90,000 0.1441% | $15.78 | $1.42M | +13.41% | ||
| 2024-01-23 | 454,545 0.5075% | $11.00 | $5M | +13.41% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 14436497 15.3953% | $36.10 | 4 | 0 | <0.0001% | |
| Thompson Peter A. | 14436497 15.3953% | $36.10 | 4 | 0 | <0.0001% | |
| Fox Jonathan C | director | 10857 0.0116% | $36.10 | 1 | 0 | |
| OrbiMed Genesis GP LLC | 13497456 14.3939% | $36.10 | 1 | 0 | +30.03% | |
| Novo Holdings A/S | 10 percent owner | 6071703 6.4749% | $36.10 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| OrbiMed | $274M | 16.08 | 15.02M | +3.12% | +$8.29M | 2.12 | |
| RA Capital Management, L.P. | $162.5M | 9.54 | 8.91M | New | +$162.5M | 0.16 | |
| Fidelity Investments | $116.11M | 6.82 | 6.37M | -1.95% | -$2.31M | 0.01 | |
| Baker Bros Advisors LP | $106.52M | 6.25 | 5.84M | +87.61% | +$49.75M | 0.77 | |
| BlackRock | $94.25M | 5.53 | 5.17M | +56.24% | +$33.92M | <0.01 |